HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

HuArgI (Co)-PEG5000

has antineoplastic activity; consists of recombinant human arginase I cobalt coupled to PEG5000

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Abdellatef, Sandra: 1 article (01/2021)
2.	Abi-Habib, Ralph: 1 article (01/2021)
3.	El-Mais, Nour: 1 article (01/2021)
4.	El-Sibai, Mirvat: 1 article (01/2021)
5.	Fakhoury, Isabelle: 1 article (01/2021)
6.	Agrawal, Vaidehi: 1 article (01/2012)
7.	Frankel, Arthur E: 1 article (01/2012)
8.	Georgiou, George: 1 article (01/2012)
9.	Jo, Chanhee: 1 article (01/2012)
10.	Mauldin, Jeremy P: 1 article (01/2012)

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 01/11/2021 - "In this study we examine the effect of HuArgI (Co)-PEG5000 on ovarian cancer cell migration and we dissect the mechanism involved. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/01/2012 - "In contrast, HuArgI (Co)-PEG5000 in combination with supplemental L-citrulline is selectively cytotoxic to a fraction of human cancer cell lines in tissue culture, including some melanomas, mesotheliomas, acute myeloid leukemias, hepatocellular carcinomas, pancreas adenocarcinomas, prostate adenocarcinomas, lung adenocarcinomas, osteosarcomas, and small cell lung carcinomas. "
3.	Osteosarcoma (Osteogenic Sarcoma) 01/01/2012 - "In contrast, HuArgI (Co)-PEG5000 in combination with supplemental L-citrulline is selectively cytotoxic to a fraction of human cancer cell lines in tissue culture, including some melanomas, mesotheliomas, acute myeloid leukemias, hepatocellular carcinomas, pancreas adenocarcinomas, prostate adenocarcinomas, lung adenocarcinomas, osteosarcomas, and small cell lung carcinomas. "
4.	Neoplasms (Cancer) 01/01/2012 - "We now show that HuArgI (Co)-PEG5000 is toxic to almost all cancer cell lines and to some normal primary cells examined. " 01/01/2012 - "On the basis of these results, we hypothesize that HuArgI (Co)-PEG5000 in combination with L-citrulline supplementation may be an attractive therapeutic agent for some argininosuccinate synthetase-deficient tumors. " 01/01/2012 - "By comparing a 3-day and 7-day exposure to HuArgI (Co)-PEG5000 with supplemental L-citrulline, some tumor cells sensitive on short-term assay are resistant in the 7-day assay consistent with the induction of argininosuccinate synthetase expression. " 01/01/2012 - "In contrast, HuArgI (Co)-PEG5000 in combination with supplemental L-citrulline is selectively cytotoxic to a fraction of human cancer cell lines in tissue culture, including some melanomas, mesotheliomas, acute myeloid leukemias, hepatocellular carcinomas, pancreas adenocarcinomas, prostate adenocarcinomas, lung adenocarcinomas, osteosarcomas, and small cell lung carcinomas. "
5.	Mesothelioma 01/01/2012 - "In contrast, HuArgI (Co)-PEG5000 in combination with supplemental L-citrulline is selectively cytotoxic to a fraction of human cancer cell lines in tissue culture, including some melanomas, mesotheliomas, acute myeloid leukemias, hepatocellular carcinomas, pancreas adenocarcinomas, prostate adenocarcinomas, lung adenocarcinomas, osteosarcomas, and small cell lung carcinomas. "

Related Drugs and Biologics

1.	Citrulline
2.	Argininosuccinate Synthase (Argininosuccinate Synthetase)